Aldeyra Therapeutics EBIT

The latest EBIT for ALDX is $-17T as of June 2026. That compares with $-10T in the prior-year period — down 71.1% year over year. That is below the Healthcare sector average of $99B. Investors often review this figure alongside Aldeyra Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, ALDX's EBIT moved from $-10T to $-17T — a 71.1% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Aldeyra Therapeutics's operating scale or balance-sheet position.

Against Healthcare companies, ALDX currently prints $-17T for EBIT, while the sector average sits near $99B. That is roughly 17629.8% below the sector mean. Large gaps often invite a closer look at Aldeyra Therapeutics's growth, margins, and balance sheet.

A EBIT figure of $-17T for ALDX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $99B. Explore the charts below for those layers of context.

After noting ALDX's EBIT ($-17T), review year-over-year change from $-10T, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.